drugset / Trial / NCT00757588

Safety and Efficacy of Saxagliptin Plus Insulin With or Without Metformin

NCT00757588

Phase 3 Completed 455 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to compare the effects of saxagliptin with those of placebo as add-on therapy to insulin and insulin with metformin in improving glycemic control at 24 and 52 weeks.

Timeline

Start
2008-11
Primary completion
2010-04
Completion
2010-04

Drugs

EvaluationDrugModalityDoseRoute
Subject SAXAGLIPTIN ANHYDROUS Small molecule 5 mg Oral
Comparator Insulin Protein / enzyme biologic